476 results on '"Machiels, J"'
Search Results
152. Time for targeted therapies in urothelial carcinoma?
153. Abstract P5-18-19: The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later
154. Abstract P3-04-04: Identification of a “BRCAness” signature in triple negative breast cancer by Comparative Genomic Hybridization
155. Biologically Based Treatment in Head and Neck Squamous Cell Carcinoma
156. Phase IB Dose-Escalation Study of BEZ235 or BKM120 in Combination with Paclitaxel (PTX) in Patients With Advanced Solid Tumors
157. Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial
158. Seeding of the percutaneous endoscopic gastrostomy site from head and neck carcinoma: Case report and review of the literature
159. Pathophysiology and new therapeutic strategies for bone metastases of prostate cancer: The sick-bed laboratory
160. P5-18-04: Safety Profile of Ixabepilone as Adjuvant Treatment for Poor Prognosis Early Breast Cancer: First Results of the Unicancer-PACS 08 Trial.
161. P3-14-13: A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2−Positive Breast Cancer Patients.
162. PP 72 Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell
163. 1204 ORAL A Phase lb Open-label Study to Assess Continuous Oral Treatment With Afatinib (BIBW 2992) in Combination With Two Chemotherapy Regimens – Cisplatin Plus Paclitaxel, and Cisplatin Plus 5-fluorouracil in Patients, With Advanced Solid Tumours
164. Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers.
165. Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies.
166. Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP).
167. 13TiP - Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
168. Critical Issues in Head and Neck Oncology
169. Abstract P5-11-13: Tamoxifen and Ovarian Function
170. Cancer and renal insufficiency results of the BIRMA study
171. An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).
172. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: GORTEC 2008-02.
173. Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery.
174. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors.
175. A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy.
176. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer.
177. Prospective Evaluation of Ovarian Function in Women with Breast Cancer Treated with Anthracyclin-Based Chemotherapy with or without Docetaxel.
178. An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+ Advanced Breast Cancer (ABC).
179. A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results
180. Phase II study of sunitinib in patients with recurrent and/or metastatic squamous head and neck carcinoma: The GORTEC 2006–01 study
181. A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer
182. Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy
183. Breast cancer and renal insufficiency.
184. A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer.
185. Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.
186. Prediction of pathological response to preoperative chemoradiotherapy with cetuximab in rectal cancer
187. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor
188. Chemoresistance gene transfer into hematopoietic cells: Hope and pitfalls
189. BRONCHOBILIARY FISTULA AND CHOLANGIOCARCINOMA: A CASE REPORT AND PRINCIPLES OF MANAGEMENT
190. PCN44 ADJUVANTTRASTUZUMAB TREATMENT IN EARLY STAGE BREAST CANCER: COST-EFFECTIVENESS IN THE BELGIAN HEALTH CARE SETTING
191. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study
192. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
193. Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
194. Tuning formulation of multipeptide vaccination for melanoma patients at high risk of relapse
195. Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC)
196. Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
197. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC)
198. Reply to Letter to the Editor ‘Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?’, by M. G. Fakih (Ann Oncol 2006; 17: 1029)
199. Carotid stenting for impending carotid blowout: suitable supportive care for head and neck cancer patients?
200. A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.